Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Trista Hinz"'
Autor:
Raphael Nemenoff, Emily Kleczko, Trista Hinz, Andre Navarro, Anh Le, Teresa Nguyen, Natalia Gurule, Amber Johnson, Jeff Kwak, Diana Polhac, Eric Clambey, Mary Weiser-Evans, Daniel Merrick, Michael Yang, Tejas Patil, Erin Schenk, Lynn Heasley
Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g. alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response are not well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af07c9bbb2b5566a16db5514a3a4e76a
https://doi.org/10.21203/rs.3.rs-2136258/v1
https://doi.org/10.21203/rs.3.rs-2136258/v1
Autor:
Vijaya G Tirunagaru, Feng Xu, Trista Hinz, Lynn Heasley, Richard Bryce, Avanish Vellanki, Nora Ku, Robert Charles Doebele
Publikováno v:
Journal of Clinical Oncology. 40:3136-3136
3136 Background: MDM2 is an E3 ubiquitin ligase that plays a critical role in the degradation of the tumor suppressor p53. Milademetan (RAIN-32) is an orally available, small molecule inhibitor of MDM2 that disrupts the MDM2-p53 complex thereby resto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::932bb7a1b49cdf0d3d12a00a0a0e8d23
https://doi.org/10.1200/jco.2022.40.16_suppl.3136
https://doi.org/10.1200/jco.2022.40.16_suppl.3136
